While first clinical trials with IDO1 inhibitors are underway, this review aims at putting the recent advances in understanding the immunobiology of TRP catabolism via IDO1/TDO in therapeutic perspective for cancer immunotherapy. The gene discussed is IDO1; the disease is cancer.